IRCT20200625047913N15尚未招募Unknown
Bioequivalence evaluation of Azithromycin Capsule 500 mg of Mahban Pharmaceutical company in comparison with brand drug
Hezareh Sevom Futuristic Pharmacist0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 45 years（—）
- 性别
- All
入选标准
- •18 to 45 years old
- •Sex: Males and/or females
- •BMI: 18.5 to 24.9 Kg/m2
- •Being able to communicate effectively with study personnel and willingness to follow the protocol requirements as evidenced by written informed consent
- •A physical examination with no clinically significant finding and laboratory normal tests
排除标准
- •Chronic or acute use of any medication at least 1 week before the start of the study
- •History of diseases affecting the pharmacokinetic processes of the drug
研究者
相似试验
尚未招募
不适用
Bioequivalence evaluation of Azithromycin Capsule 500 mg/ Suspension 200 mg/5 ml manufactured by Dora Darou company-.IRCT20200625047913N3Hezareh Sevom Futuristic Pharmacist24
已完成
Unknown
Bioequivalence evaluation of Azithromycin Tablet 100 mg of Mahban Pharmaceutical companyIRCT20200625047913N10Hezareh Sevom Futuristic Pharmacist24
招募中
不适用
In-vivo Bioequivalence study of Azithromycin capsules 250 mg with brand drugs (ZITHROMAX® 250 mg Pfizer, Ireland)IRCT20200105046010N37Kharazmi Pharmaceutical Co24
已完成
不适用
Bioequivalence study of Azithromycin 250 mgIRCT20200623047902N8Sanamed pharma company24
已完成
不适用
Bioequivalence study of Azithromycin 500 mg tabletThis study is performed on healthy volunteers..IRCT20200623047902N13Sanamed pharma company24